AAD Backs Arcutis’ ZORYVE for Pediatric Atopic Dermatitis in Landmark Guidelines — Arcutis Biotherapeutics, Inc.

Event summary

Arcutis’ ZORYVE cream received a strong recommendation in the AAD’s first-ever pediatric atopic dermatitis guidelines, with high certainty of clinical evidence.
The guidelines recommend ZORYVE for children aged 2-5 years (0.05% formulation) and those aged 6+ (0.15% formulation).
ZORYVE is positioned as a steroid-free, long-term topical therapy with low discontinuation rates in pediatric patients.
Atopic dermatitis affects ~9.6 million children in the U.S., making this a significant market opportunity.

The big picture

The AAD’s strong endorsement of ZORYVE underscores its growing role in dermatology, particularly as a steroid-free alternative for long-term use. This aligns with broader industry trends favoring targeted topical therapies that balance efficacy and safety, especially in pediatric populations where skin barrier integrity is critical.

What we're watching

Market Expansion: Whether Arcutis can leverage this endorsement to gain market share in the pediatric atopic dermatitis segment.
Clinical Adoption: The pace at which dermatologists incorporate ZORYVE into treatment protocols for pediatric patients.
Competitive Dynamics: How this recommendation positions ZORYVE against existing and emerging therapies in the atopic dermatitis space.